Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

NCT00943943 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelogenous Leukemia
Leukemia

Interventions

DRUG: G-CSF
DRUG: Plerixafor
DRUG: Sorafenib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]